Handelsbanken Fonder’s Acceleron Pharma XLRN Stock Holding History

Handelsbanken Fonder’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-159,523	Closed	-$27.5M	–	1786
2021 Q3	$27.5M	Buy	159,523 +11,000	+7%	+$1.44M	0.14%	158
2021 Q2	$18.6M	Buy	148,523 +12,600	+9%	+$1.59M	0.1%	222
2021 Q1	$18.4M	Sell	135,923 -15,900	-10%	-$2.05M	0.1%	193
2020 Q4	$19.4M	Hold	151,823	–	–	0.12%	178
2020 Q3	$17.1M	Buy	151,823 +144,000	+1,841%	+$14.3M	0.13%	172
2020 Q2	$745K	Buy	+7,823	New	+$754K	0.01%	793

Handelsbanken Fonder's XLRN Position: Q4 2021 in Review

Handelsbanken Fonder sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 159,523 shares — an estimated $27.5M sold.

Handelsbanken Fonder first reported a position in XLRN in Q2 2020 and held it in 6 quarters. The position peaked at $27.5M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

Handelsbanken Fonder reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
Handelsbanken Fonder sold 159,523 Acceleron Pharma shares in Q4 2021, an estimated $27.5M.
Handelsbanken Fonder first reported a position in Acceleron Pharma in Q2 2020 and held it in 6 quarters.
Handelsbanken Fonder's Acceleron Pharma position peaked at $27.5M in Q3 2021.
1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Handelsbanken Fonder's 13F filing for Q4 2021, filed 8 Feb 2022.